id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-N-0441-0005,FDA,FDA-2003-N-0441,Background Material re Exocrine Pancreatic Insufficiency Drug Products,Supporting & Related Material,Background Material,2009-04-15T04:00:00Z,2009,4,,,2025-03-05T19:53:43Z,,0,0,09000064804a2447
FDA-2003-N-0441-0004,FDA,FDA-2003-N-0441,Background Material re Exocrine Pancreatic Insufficiency Drug Products,Supporting & Related Material,Background Material,2009-04-15T04:00:00Z,2009,4,,,2025-03-05T19:53:01Z,,0,0,09000064804a243d
FDA-2003-N-0441-0002,FDA,FDA-2003-N-0441,Exocrine Pancreatic Insufficiency Drug Products; Extension to Obtain Marketing Approval,Notice,General Notice,2007-10-26T04:00:00Z,2007,10,2007-10-26T04:00:00Z,,2025-03-05T19:50:55Z,E7-21082,0,0,09000064804a245c
FDA-2003-N-0441-0001,FDA,FDA-2003-N-0441,Exocrine Pancreatic Insufficiency Drug Products,Notice,General Notice,2004-05-07T04:00:00Z,2004,5,,,2025-03-05T16:18:50Z,04-9652,0,0,09000064804a2437